Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W. Green purchased 20,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was acquired at an average price of $2.47 per share, with a total value of $49,400.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
NASDAQ HBIO opened at $2.48 on Thursday. The company has a market capitalization of $95.88 million, a price-to-earnings ratio of 16.53 and a beta of 1.51. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.12 and a current ratio of 2.22. The stock has a 50-day simple moving average of $2.13. Harvard Bioscience, Inc. has a twelve month low of $1.51 and a twelve month high of $6.70.
Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. Harvard Bioscience had a positive return on equity of 5.22% and a negative net margin of 0.46%. The company had revenue of $29.58 million during the quarter, compared to analyst estimates of $29.30 million. On average, sell-side analysts forecast that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of Harvard Bioscience in the 2nd quarter valued at $357,000. Citadel Advisors LLC acquired a new position in shares of Harvard Bioscience in the 2nd quarter valued at $118,000. Jefferies Group LLC acquired a new position in shares of Harvard Bioscience in the 2nd quarter valued at $36,000. Marshall Wace LLP boosted its holdings in shares of Harvard Bioscience by 377.0% in the 2nd quarter. Marshall Wace LLP now owns 412,848 shares of the medical instruments supplier’s stock valued at $826,000 after purchasing an additional 326,305 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Harvard Bioscience by 808.7% in the 2nd quarter. Morgan Stanley now owns 68,414 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 60,885 shares during the last quarter. 76.39% of the stock is owned by institutional investors.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Featured Story: What is a good rate of return for a mutual fund?
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.